A1 Refereed original research article in a scientific journal
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation
Authors: Laban S, Steinmeister L, Gleißner L, Grob TJ, Grénman R, Petersen C, Gal A, Knecht R, Dikomey E, Kriegs M
Publication year: 2013
Journal: Radiotherapy and Oncology
Number in series: 2
Volume: 109
Issue: 2
First page : 286
Last page: 292
Number of pages: 7
ISSN: 0167-8140
DOI: https://doi.org/10.1016/j.radonc.2013.07.003
BACKGROUND AND PURPOSE:
There is a great need to improve the outcome of locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment includes a combination of surgery, radio- and chemotherapy. The addition of molecular targeting agents to conventional treatment may improve outcomes. In this study the Raf inhibitor sorafenib was used to increase the radiosensitivity of HNSCC cell lines.
MATERIAL AND METHODS:
In a panel of six cell lines (A549, FaDu, UTSCC 60A, UTSCC 42A, UTSCC 42B, UTSCC 29) radiosensitivity was measured by colony formation assay and apoptosis and cell cycle analysis were performed by flow cytometry. DNA repair was analyzed by 53BP1 immunohistochemistry.
RESULTS:
Sorafenib added prior to irradiation resulted in an increased cellular radiosensitivity (DEF0.5=1.11-1.84). Radiosensitization was not caused by an enhanced rate of apoptosis or cell cycle effects. In contrast, sorafenib was shown for the first time to block the repair of DNA double-strand breaks (DSB).
CONCLUSION:
Our data suggest that sorafenib may be used to overcome the radioresistance of HNSCC through the inhibition of DSB repair.
